Fulltext

Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management

Wensing, Annemarie M. J. ; van de Vijver, David A. ; Angarano, Gioacchino ; Åsjö, Birgitta ; Balotta, Claudia ; Boeri, Enzo ; Camacho, Ricardo ; Chaix, Maire-Laure ; Costagliola, Dominique ; De Luca, Andrea ; Derdelinckx, Inge ; Grossman, Zehava ; Hamouda, Osamah ; Hatzakis, Angelos ; Hemmer, Robert ; Hoepelman, Andy ; Horban, Andrzej ; Korn, Klaus ; Kücherer, Claudia ; Leitner, Thomas ; Loveday, Clive ; MacRae, Eilidh ; Maljkovic, Irina ; de Mendoza, Carmen ; Meyer, Laurence ; Nielsen, Claus ; Op de Coul, Eline L. ; Ormaasen, Vidar ; Paraskevis, Dimitris ; Perrin, Luc ; Puchhammer-Stöckl, Elisabeth ; Ruiz, Lidia ; Salminen, Mika ; Schmit, Jean-Claude ; Schneider, Francois ; Schuurman, Rob ; Soriano, Vincent ; Stanczak, Grzegorz ; Stanojevic, Maja ; Vandamme, Anne-Mieke ; Van Laethem, Kristel ; Violin, Michela ; Wilbe, Karin ; Yerly, Sabine ; Zazzi, Maurizio ; Boucher, Charles A.

In: The Journal of Infectious Diseases, 2005, vol. 192, no. 6, p. 958-966

Add to personal list
    Title
    • Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management
    Author
    • Wensing, Annemarie M. J.. Eijkman Winkler Institute, Department of Virology
    • van de Vijver, David A.. Eijkman Winkler Institute, Department of Virology
    • Angarano, Gioacchino. University of Foggia, Foggia
    • Åsjö, Birgitta. University of Bergen, Bergen
    • Balotta, Claudia. University of Milan
    • Boeri, Enzo. Diagnostica e Ricerca San Raffaele, Milan
    • Camacho, Ricardo. Hospital Egas Moniz, Lisbon, Portugal
    • Chaix, Maire-Laure. Laboratoire de Virologie, Hôspital Necker
    • Costagliola, Dominique. U720 INSERM and Université Pierre et Marie Curie, Paris
    • De Luca, Andrea. Institute of Clinical Infectious Diseases, Catholic University, Rome
    • Derdelinckx, Inge. Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium
    • Grossman, Zehava. Sheba Medical Center, Tel-Hashomer, Israel
    • Hamouda, Osamah. Robert Koch Institute, Berlin, Germany
    • Hatzakis, Angelos. Athens University Medical School, Athens, Greece
    • Hemmer, Robert. Centre Hospitalier de Luxembourg, Luxembourg
    • Hoepelman, Andy. Department of Internal Medicine, University Medical Center Utrecht, Utrecht
    • Horban, Andrzej. Hospital for Infectious Diseases and AIDS Diagnosis and Therapy Center, Warsaw, Poland
    • Korn, Klaus. University of Erlangen, Erlangen
    • Kücherer, Claudia. Robert Koch Institute, Berlin, Germany
    • Leitner, Thomas. Los Alamos National Laboratory, Los Alamos, New Mexico
    • Loveday, Clive. International ClinicalVirology Centre, High Wycombe, United Kingdom
    • MacRae, Eilidh. International ClinicalVirology Centre, High Wycombe, United Kingdom
    • Maljkovic, Irina. Swedish Institute for Infectious Disease Control, Solna, Sweden
    • de Mendoza, Carmen. Hospital Carlos III, Madrid, Spain
    • Meyer, Laurence. INSERM U569, Kremlin-Bicêtre, France
    • Nielsen, Claus. Statens Serum Institute, Copenhagen, Denmark
    • Op de Coul, Eline L.. National Institute for Public Health and the Environment, Bilthoven, The Netherlands
    • Ormaasen, Vidar. Ullevaal University Hospital, Oslo, Norway
    • Paraskevis, Dimitris. Athens University Medical School, Athens, Greece
    • Perrin, Luc. Geneva University Hospital, Geneva, Switzerland
    • Puchhammer-Stöckl, Elisabeth. University of Vienna, Vienna, Austria
    • Ruiz, Lidia. Retrovirology Laboratory IrsiCaixa Foundation, Badalona, Spain
    • Salminen, Mika. National Public Health Institute, Helsinki, Finland
    • Schmit, Jean-Claude. Centre Hospitalier de Luxembourg, Luxembourg
    • Schneider, Francois. Centre Hospitalier de Luxembourg, Luxembourg
    • Schuurman, Rob. Eijkman Winkler Institute, Department of Virology
    • Soriano, Vincent. Hospital Carlos III, Madrid, Spain
    • Stanczak, Grzegorz. Hospital for Infectious Diseases and AIDS Diagnosis and Therapy Center, Warsaw, Poland
    • Stanojevic, Maja. University of Belgrade, Belgrade, Serbia-Montenegro
    • Vandamme, Anne-Mieke. Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium
    • Van Laethem, Kristel. Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium
    • Violin, Michela. University of Milan
    • Wilbe, Karin. Swedish Institute for Infectious Disease Control, Solna, Sweden
    • Yerly, Sabine. Geneva University Hospital, Geneva, Switzerland
    • Zazzi, Maurizio. University of Siena, Siena, Italy
    • Boucher, Charles A.. Eijkman Winkler Institute, Department of Virology
    Document Type
    • Postprint
    Language
    • English
    Published in
    • The Journal of Infectious Diseases, 2005, vol. 192, no. 6, p. 958-966. The University of Chicago Press
    Other Version
    Classification
    • Health
    OAI-PMH Identifier
    • oai:doc.rero.ch:301781
    Summary
    BackgroundInfection with drug-resistant human immunodeficiency virus type 1 (HIV-1) can impair the response to combination therapy. Widespread transmission of drug-resistant variants has the disturbing potential of limiting future therapy options and affecting the efficacy of postexposure prophylaxis penta increase-spacing 1>MethodsWe determined the baseline rate of drug resistance in 2208 therapy-naive patients recently and chronically infected with HIV-1 from 19 European countries during 1996-2002 ResultsIn Europe, 1 of 10 antiretroviral-naive patients carried viruses with ⩾1 drug-resistance mutation. Recently infected patients harbored resistant variants more often than did chronically infected patients (13.5% vs. 8.7%; P=.006). Non-B viruses (30%) less frequently carried resistance mutations than did subtype B viruses (4.8% vs. 12.9%; P<.01). Baseline resistance increased over time in newly diagnosed cases of non-B infection: from 2.0% (1/49) in 1996-1998 to 8.2% (16/194) in 2000-2001 ConclusionsDrug-resistant variants are frequently present in both recently and chronically infected therapy-naive patients. Drug-resistant variants are most commonly seen in patients infected with subtype B virus, probably because of longer exposure of these viruses to drugs. However, an increase in baseline resistance in non-B viruses is observed. These data argue for testing all drug-naive patients and are of relevance when guidelines for management of postexposure prophylaxis and first-line therapy are updated